Magnetic nanoparticles for lab-quality immunoassay results at the point of care


Philips has developed a biosensor technology which has the potential to offer lab-quality immunoassay results at the point of care. This new “Magnotech” technology uses magnetic nanoparticles to measure target molecules and could bring complex in-vitro diagnostic tests out of the laboratory and into decentralized settings such as the patient’s bedside and at home.

A first collaboration agreement for the new technology was recently announced, with Concateno, a UK-based leading European company in drugs of abuse testing. Concateno and Philips will deliver the new solution to selected customers in 2009. At launch, the Concateno-Philips handheld product will test five drug groups at the same time (cocaine, heroin, methamphetamine, amphetamine and cannabis) in a single saliva sample. Total test time of the new device, from collection of sample to result, will be less than 90 seconds.

[Sources : articles 1, 2, 3, 4]